Insight Molecular Diagnostics Return on Tangible Equity 2014-2026 | IMDX
Current and historical return on tangible equity values for Insight Molecular Diagnostics (IMDX) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Insight Molecular Diagnostics Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2026-06-30 | $-0.05B | $-0.02B | 225.29% |
| 2026-03-31 | $-0.05B | $-0.02B | 240.00% |
| 2025-12-31 | $-0.05B | $-0.02B | 279.45% |
| 2025-09-30 | $-0.06B | $-0.02B | 353.62% |
| 2025-06-30 | $-0.06B | $-0.02B | 273.91% |
| 2025-03-31 | $-0.06B | $-0.03B | 207.14% |
| 2024-12-31 | $-0.06B | $-0.04B | 156.86% |
| 2024-09-30 | $-0.04B | $-0.04B | 108.64% |
| 2024-06-30 | $-0.04B | $-0.03B | 113.43% |
| 2024-03-31 | $-0.04B | $-0.03B | 145.13% |
| 2023-12-31 | $-0.03B | $-0.02B | 133.33% |
| 2023-09-30 | $-0.06B | $-0.02B | 292.31% |
| 2023-06-30 | $-0.06B | $-0.02B | 269.66% |
| 2023-03-31 | $-0.06B | $-0.03B | 237.62% |
| 2022-12-31 | $-0.07B | $-0.03B | 217.91% |
| 2022-09-30 | $-0.06B | $-0.03B | 209.84% |
| 2022-06-30 | $-0.07B | $-0.03B | 261.54% |
| 2022-03-31 | $-0.07B | $-0.02B | 297.87% |
| 2021-12-31 | $-0.06B | $0.00B | -3657.14% |
| 2021-09-30 | $-0.03B | $0.01B | -438.71% |
| 2021-06-30 | $-0.03B | $0.01B | -203.77% |
| 2021-03-31 | $-0.03B | $0.02B | -125.30% |
| 2020-12-31 | $-0.03B | $0.01B | -260.87% |
| 2020-09-30 | $-0.03B | $0.02B | -188.24% |
| 2020-06-30 | $-0.03B | $0.02B | -137.93% |
| 2020-03-31 | $-0.03B | $0.03B | -98.11% |
| 2019-12-31 | $-0.02B | $0.03B | -66.67% |
| 2019-09-30 | $-0.02B | $0.03B | -73.08% |
| 2019-06-30 | $-0.02B | $0.02B | -81.93% |
| 2019-03-31 | $-0.02B | $0.01B | -121.43% |
| 2018-12-31 | $-0.02B | $0.01B | -261.54% |
| 2018-09-30 | $-0.02B | $0.01B | -237.04% |
| 2018-06-30 | $-0.02B | $0.01B | -307.69% |
| 2018-03-31 | $-0.02B | $0.01B | -316.67% |
| 2017-12-31 | $-0.02B | $0.01B | -333.33% |
| 2017-09-30 | $-0.02B | $0.01B | -262.07% |
| 2017-06-30 | $-0.02B | $0.01B | -176.47% |
| 2017-03-31 | $-0.01B | $0.01B | -175.00% |
| 2016-12-31 | $-0.01B | $0.01B | -160.00% |
| 2016-09-30 | $-0.01B | $0.01B | -173.33% |
| 2016-06-30 | $-0.01B | $0.01B | -266.67% |
| 2016-03-31 | $-0.01B | $0.00B | -266.67% |
| 2015-12-31 | $-0.01B | $0.00B | -355.56% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.132B | $0.004B |
| Insight Molecular Diagnostics Inc. is a pioneering diagnostics technology company. Insight Molecular Diagnostics Inc., formerly known as Oncocyte Corporation, is based in NASHVILLE, Tenn. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $43.014B | 42.92 |
| Tempus AI (TEM) | United States | $11.225B | 0.00 |
| 10x Genomics (TXG) | United States | $9.135B | 0.00 |
| Hinge Health (HNGE) | United States | $7.649B | 73.48 |
| Hims & Hers Health (HIMS) | United States | $6.722B | 0.00 |
| Doximity (DOCS) | United States | $4.704B | 29.00 |
| Heartflow (HTFL) | United States | $4.308B | 0.00 |
| IRhythm Holdings (IRTC) | United States | $3.782B | 249.39 |
| Clover Health Investments (CLOV) | United States | $2.709B | 0.00 |
| Privia Health (PRVA) | United States | $2.667B | 99.43 |
| Inspire Medical Systems (INSP) | United States | $2.149B | 32.74 |
| Butterfly Network (BFLY) | United States | $1.973B | 0.00 |
| Schrodinger (SDGR) | United States | $1.532B | 0.00 |
| Omnicell (OMCL) | United States | $1.524B | 21.76 |
| Azenta (AZTA) | United States | $1.404B | 76.29 |
| Enovis (ENOV) | United States | $1.051B | 5.44 |
| Talkspace (TALK) | United States | $0.879B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.659B | 0.00 |
| Phreesia (PHR) | United States | $0.647B | 34.73 |
| Claritev (CTEV) | United States | $0.618B | 0.00 |
| Veradigm (MDRX) | United States | $0.593B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.568B | 0.00 |
| Evolent Health (EVH) | United States | $0.464B | 0.00 |
| Carlsmed (CARL) | United States | $0.419B | 0.00 |
| Senseonics Holdings (SENS) | United States | $0.370B | 0.00 |
| CapsoVision (CV) | United States | $0.326B | 0.00 |
| Standard BioTools (LAB) | United States | $0.273B | 0.00 |
| American Well (AMWL) | United States | $0.230B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.144B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.137B | 0.00 |
| CareCloud (CCLD) | United States | $0.089B | 6.53 |
| Pulmonx (LUNG) | United States | $0.085B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.065B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.062B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.060B | 0.00 |
| Outset Medical (OM) | United States | $0.059B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.050B | 0.00 |
| Precipio (PRPO) | United States | $0.049B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.035B | 0.00 |
| 111 (YI) | China | $0.031B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.026B | 0.00 |
| HeartBeam (BEAT) | United States | $0.023B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.020B | 0.00 |
| HeartSciences (HSCS) | United States | $0.014B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.011B | 0.00 |
| Lunai Bioworks (LNAI) | United States | $0.010B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.009B | 0.00 |
| ITonic Holdings (ITOC) | China | $0.005B | 0.00 |
| DataMeds AI (MEDS) | United States | $0.003B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.003B | 0.00 |
| PROFUSA (PFSA) | United States | $0.002B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.001B | 0.00 |
| Zhongchao (ZCMD) | China | $0.001B | 0.00 |
| TruBridge (TBRG) | United States | $0.000B | 0.00 |